Appointment; HIV study progress
Immune Network Research Ltd IMM
Shares issued 19,970,452 Jul 17 close $0.17
Mon 20 Jul 98 News Release
VANCOUVER, B.C. (July 20, 1998) - Victor Jones, President, is very pleased
to announce the appointment of Brian Conway MD, FRCPC to the Scientific
Advisory Board of the Company. Dr. Conway is one of the leading experts in
the field of HIV virology, and has published over 40 articles in peer
reviewed journals in the field since completing a specialty in infectious
disease at the University of Manitoba in 1988. He has been the recipient of
a number of industrial and academic grants for the study of antiviral
therapies and the virology of HIV infection. His research interest and
expertise in HIV therapies and the measurement of the efficacy of therapy
make him uniquely qualified to participate in the development of novel
immune-based strategies to control HIV in infected patients.
Dr. Conway has recently moved to Viridae Clinical Sciences Inc. in
Vancouver as its Medical Director, joining Dr. Steven Sacks, its CEO to
establish a comprehensive laboratory and clinical virology research program
in the fields of herpes, hepatitis and HIV. Viridae is an integrated
virology research organization which has the infrastructure to develop new
studies of promising antiviral compounds from initial inception to their
approval by regulatory authorities. Dr. Conway remains on staff at the
University of British Columbia as an Assistant Professor in the Department
of Pharmacology and Therapeutics.
Dr. Conway joins Dr. Michael Grant (Memorial University), Dr. Heinz K”hler
(University of Kentucky) and Dr. Ken Rosenthal (McMaster University) on the
Scientific Advisory Board of the Company to assist with plans for clinical
trials of its proprietary monoclonal antibody 1F7 and review of new
projects to expand on its core technology.
The Company is on day 105 of a six month study of the effects on the immune
system of macaque monkeys, a preferred model for the study of HIV disease
in humans. This work involves nine macaques at the Oregon Regional Primate
Centre and is evaluating the breadth and potency of the antibody as a means
of strengthening immune system response to HIV infection. Under the
direction of Dr. Sybille Mller, Vice President of Immpheron, Inc. based in
Lexington, KY, which is the company's joint venture partner on the project,
the current study is a follow up to an earlier study. In that study
beneficial effects on the immune system of SHIV infected macaques were
reported and 1F7 normalized the immune response fighting the viral
infection in the monkeys. Preliminary discussions have been held with the
FDA on the production by Immpheron, Inc. of monoclonal antibody 1F7 for
clinical trials in infected patients with 1F7 as an Investigational New
Drug (IND).
"signed"
Victor J.E. Jones
President
THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS
RELEASE
Immune Network Research Ltd.
900 - 475 Howe Street
Vancouver, B.C., Canada V6C 2B3
Tel. (604) 689-3923; Fax. (604) 684-5854
www.stockgroup.com/imm.html |
